|
SciGen Announces Marketing Approval of its Recombinant Human Insulin SciLin™ in Hong Kong |
|
|
|
21 Dec 2006 |
Announces marketing approval of its Recombinant human Insulin SciLIn™ in Hong Kong. The product will be promoted by SciGen Sales & Marketing group in Hong Kong. SciGen expects to launch the product in the first quarter of 2007.
HONG KONG, China | Dec 21, 2006 | SciGen Limited (ASX: SIE) announces marketing approval of its Recombinant human Insulin SciLIn™ in Hong Kong. The product will be promoted by SciGen Sales & Marketing group in Hong Kong. SciGen expects to launch the product in the first quarter of 2007.
About SciLin:
SciLin is a second generation recombinant human insulin expressed in E. coli. SciLin™ contains insulin produced by recombinant DNA technology using a special non-disease producing strain of E. coli cell bacteria. The insulin molecule in SciLin™ is identical to natural human insulin in composition and in three-dimensional conformation. SciLin™ is used for type I and type II diabetes.
The need for Generic Insulin continues to grow. Currently, the total world market for insulin is estimated to be US$3.6 billion per annum and that for all diabetes therapeutics is forecast to grow by 20% per anum over the medium term. SciGen’s immediate target regions include India, China and Pakistan, which rank among the five largest populations of diabetes in the world.
About SciGen:
SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.
SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands
SOURCE: SciGen Ltd. |
